Meanwhile, ZDHHC3 expression was incompatible with PD-1, CTLA4, and LAG3 expression levels in some tumors, including pancreatic cancer, and suggested that the immunomodulatory effects of ZDHHC3 have the potential to be used in combination with these immune checkpoint blockade. This evidence concerns the gene CTLA4 and familial pancreatic carcinoma.